PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE

Abstract

Topical pharmaceutical composition as a dispersed phase based on a short diol in a continuous fatty phase and including an anti-inflammatory substance, the composition including: a gelled phase including an anti-inflammatory substance and a diol including 3-8 carbon atoms and represented either by formula (I.sub.a): R.sup.a.sub.1—(R.sup.b.sub.1)(OH)—(OH)(R.sup.c.sub.1)(R.sup.d.sub.1) (I.sub.a), in which each of the radicals R.sup.a.sub.1, R.sup.b.sub.1, R.sup.c.sub.1 and R.sup.d.sub.1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including 1-5 carbon atoms, or by formula (I.sub.b): R.sup.a.sub.1—C(R.sup.b.sub.1)(OH)—[C(R.sup.e.sub.1)(Rf.sub.1)].sub.t—C(OH)(R.sup.c.sub.1)(R.sup.d.sub.1) (I.sub.b), t=1, 2 or 3, each of the radicals R.sup.a.sub.1, R.sup.b.sub.1, R.sup.c.sub.1 R.sup.d.sub.1, R.sup.e.sub.1 and R.sup.f.sub.1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including 1-5 carbon atoms. The radicals R.sup.a.sub.1or R.sup.b.sub.1 and/or the radicals R.sup.c.sub.1or R.sup.d.sub.1does not represent a hydrogen atom, a fatty phase including an oil and an emulsifying system including a combination of emulsifying surfactants.

Claims

1. A pharmaceutical composition (E1) suitable for topical use comprising a gelled phase (A1) dispersed in a continuous phase (A2), said pharmaceutical composition (E1) comprising: a gelled phase (A1) free of added water and comprising at least one anti-inflammatory substance (AI) and at least one diol including from 3 to 8 carbon atoms and represented either by formula (I.sub.a):
R.sup.a.sub.1—C(R.sup.b.sub.1)(OH)—C(OH)(R.sup.c.sub.1)(R.sup.d.sub.1)  (I.sub.a), in which each of the radicals R.sup.a.sub.1, R.sup.b.sub.1, R.sup.c.sub.1 and R.sup.d.sub.1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including from 1 to 5 carbon atoms, or by formula (I.sub.b):
R.sup.a.sub.1—C(R.sup.b.sub.1)(OH)—[C(OH)(R.sup.e.sub.1)(R.sup.f.sub.1)].sub.t—C(OH)(R.sup.c.sub.1)(R.sup.d.sub.1)  (I.sub.b), in which t is equal to 1, 2 or 3, each of the radicals R.sup.a.sub.1, R.sup.b.sub.1, R.sup.c.sub.1, R.sup.d.sub.1, R.sup.e.sub.1 and R.sup.f1 represents, independently of each other, a hydrogen atom or a saturated aliphatic radical including from 1 to 5 carbon atoms, it being understood that at least one of the radicals R.sup.a.sub.1 or R.sup.b.sub.1 and/or at least one of the radicals R.sup.c.sub.1 or R.sup.d.sub.1 do not represent a hydrogen atom; a fatty phase (A2) comprising at least one oil and an emulsifying system (S) comprising a combination of at least one emulsifying surfactant (S1) and at least one emulsifying surfactant (S2).

2. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, comprising, per 100% of its mass: from 60% to 98% by mass of the gelled phase (A1), and from 2% to 40% by mass of the fatty phase (A2).

3. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein: the emulsifying surfactant (S1) is selected from the elements of the group consisting of alkylpolyglycoside compositions, and alkylpolyglycoside and fatty alcohol compositions, and the emulsifying surfactant (S2) is selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

4. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the gelled phase (A1) comprises, per 100% of its mass: from 0.625% to 10% by mass of a crosslinked anionic polyelectrolyte (API), from 0.625% to 5% by mass of at least one anti-inflammatory substance (AI), from 85% to 98.75% by mass of at least one diol including from 3 to 8 carbon atoms and represented either by formula (I.sub.a), or by formula (I.sub.b).

5. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein said diol including from 3 to 8 carbon atoms and represented either by formula (Ia) or by formula (Ib) is chosen from 1,2-propanediol, 1,2-butanediol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 2,3-butanediol, 2,3-pentanediol, 2,3-hexanediol, 2,5-hexanediol or 2-methyl-2,4-pentanediol.

6. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 5, wherein said diol including from 3 to 8 carbon atoms and represented either by formula (I.sub.a) or by formula (I.sub.b) is chosen from 1,2-propanediol, 1,2-butanediol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol or 2-methyl-2,4-pentanediol.

7. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the crosslinked anionic polyelectrolyte (AP1) comprises a proportion of greater than or equal to 25 mol % of monomer units derived from 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid in free acid or partially or totally salified form.

8. The pharmaceutical composition (E1) for suitable topical use as claimed in claim 1, wherein the anti-inflammatory substance (AI) is chosen from the alkali metal, alkaline-earth metal, ammonium, N,N-dialkylammonium and N,N,N-trialkylammonium salts for which each of the alkyl groups includes between 1 and 4 carbon atoms, of the elements of the group consisting of 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid (CAS number=15307-86-5) or diclofenac of formula (AIa): ##STR00021## 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid (CAS number=89796-99-6) or aceclofenac of formula (AIb), ##STR00022## 2-(5-benzoylthiophen-2-yl)propanoic acid (CAS number=33005-95-7 (RS)) or tiaprofenic acid in the R enantiomer form of formula (AIc1) and in the S enantiomer form of formula (AIc2) ##STR00023## 2-[4-(2-methylprop-2-enylamino)phenyl]propanoic acid (CAS number=39718-89-3) or alminoprofen of formula (AId), ##STR00024## 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid (CAS number=41340-25-4) or etodolac of formula (AIe), ##STR00025## (±)-2-fluoro-α-methyl-(1,1′-biphenyl)-4-acetic acid or flurbiprofen in the R enantiomer form of formula (AIf1) and in the S enantiomer form of formula (AIf2), (CAS number=5104-49-4 (RS)): ##STR00026## 2-[4-(2-methylpropyl)phenyl]propanoic acid or ibuprofen in the R enantiomer form of formula (AIg1) and in the S enantiomer form of formula (AIg2), (CAS number=15687-27-1 (RS)): ##STR00027## 2-(3-benzoylphenyl)propionic acid in the S(+) enantiomer form (CAS number=22161-81-5) and R(−) enantiomer form (CAS number=56105-81-8) and in the form of a racemic mixture (CAS number=22071-15-4) or ketoprofen of formula (AIh), ##STR00028## 6-methoxy-α-methyl-2-naphthaleneacetic acid or naproxen in the S(+) enantiomer form (CAS number=22204-53-1) of formula (Ii) or in the form of a racemic mixture (CAS number=23981-80-8): ##STR00029##

9. The pharmaceutical composition suitable for topical use as claimed in claim 1, wherein the anti-inflammatory substance (AI) is chosen from the sodium salt of 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid, the diethylammonium salt of 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid, the sodium salt of 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid, the diethylammonium salt of 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid, the sodium salt of 2-[4-(2-methylpropyl)phenyl]propanoic acid, and the sodium salt of 2-(3-benzoylphenyl)propionic acid.

10. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the fatty phase (A2) comprises, per 100% of its mass: from 1.25% to 25% by mass of an emulsifying system (S) comprising, per 100% by mass of said emulsifying system (S): from 12% to 88% by mass of at least one emulsifying surfactant (S.sub.1) selected from the elements of the group consisting of alkylpolyglycoside compositions, alkylpolyglycoside and fatty alcohol compositions, and from 12% to 88% by mass of at least one emulsifying surfactant (S2) selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates; from 75% to 98.75% by mass of at least one oil.

11. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the emulsifying surfactant (S.sub.1) consists of at least one alkylpolyglycoside composition (C.sub.1) represented by formula (VII):
R.sub.1—O-(G)x-H   (VII) in which x represents a decimal number between 1.05 and 2.5, G represents the glucosyl or α,β-D-glucopyranosyl radical, obtained from the removal of the hemiacetal hydroxyl group from α,β-D-glucopyranose, and R.sub.1 represents a radical chosen from the elements of the group consisting of the n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl radicals, said composition (C.sub.1) consisting of a mixture of compounds represented by formulae (VII.sub.1), (VII.sub.2), (VII.sub.3), (VII.sub.4) and (VII.sub.5):
R.sub.1—O-(G).sub.1-H   (VII.sub.1)
R.sub.1—O-(G).sub.2-H   (VII.sub.2)
R.sub.1—O-(G).sub.3-H   (VII.sub.3)
R.sub.1—O-(G).sub.4-H   (VII.sub.4)
R.sub.1—O-(G).sub.5-H   (VII.sub.5), in the respective molar proportions a.sub.1, a.sub.2, a.sub.3, a.sub.4 and a.sub.5 such that: the sum a.sub.1+a.sub.2+a.sub.3+a.sub.4+a.sub.5 is equal to 1 and that the sum a.sub.1+2a.sub.2+3a.sub.3+4a.sub.4+5a.sub.5 is equal to x.

12. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the emulsifying surfactant (S.sub.1) consists of at least one composition (C.sub.2) comprising, per 100% of its mass: from 10% to 50% by mass of at least one alkylpolyglycoside composition (C.sub.1) represented by formula (VII):
R.sub.1—O-(G).sub.x-H   (VII), in which x represents a decimal number between 1.05 and 2.5, G represents the glucosyl or α,β-D-glucopyranosyl radical, obtained from the removal of the hemiacetal hydroxyl group from α,β-D-glucopyranose, and R.sub.1 represents a radical chosen from the elements of the group consisting of the n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl radicals, said composition consisting of a mixture of compounds represented by formulae (VII.sub.1), (VII.sub.2), (VII.sub.3), (VII.sub.4) and (VII.sub.5):
R.sub.1—O-(G)1-H   (VII1)
R.sub.1—O-(G)2-H   (VII2)
R.sub.1—O-(G)3-H   (VII3)
R.sub.1—O-(G)4-H   (VII4)
R.sub.1—O-(G)5-H   (VII5) in the respective molar proportions a.sub.1, a.sub.2, a.sub.3, a.sub.4 and a.sub.5 such that: the sum a.sub.1+a.sub.2+a.sub.3+a.sub.4+a.sub.5 is equal to 1 and that the sum a.sub.1+2a.sub.2+3a.sub.3+4a.sub.4+5a.sub.5 is equal to x; and from 50% to 90% by mass of at least one fatty alcohol of formula (VIII):
R″.sub.1—OH  (VIII), in which R″.sub.1 represents a radical chosen from the elements of the group consisting of the n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl radicals, where R″.sub.1 may be identical to or different from R.sub.1.

13. The pharmaceutical composition (E1) suitable for topical use as defined in claim 1, wherein the emulsifying surfactant (S.sub.1) consists of at least one alkylpolyglycoside composition (C′.sub.1) represented by formula (IX):
R.sub.1—O-(G).sub.x-H   (IX) in which x represents a decimal number between 1.05 and 2.5, G represents a xylosyl or α,β-D-xylopyranosyl radical, obtained from the removal of the hemiacetal hydroxyl group from α,β-D-xylopyranose, and R.sub.1 represents a 2-octyldodecyl radical, said composition (C′.sub.1) consisting of a mixture of compounds represented by formulae (IX.sub.1), (IX.sub.2), (IX.sub.3), (IX.sub.4) and (IX.sub.5):
R.sub.1—O-(G).sub.1-H   (IX.sub.1)
R.sub.2—O-(G).sub.2-H   (IX.sub.2)
R.sub.3—O-(G).sub.3-H   (IX.sub.3)
R.sub.4—O-(G).sub.4-H   (IX.sub.4)
R.sub.5—O-(G).sub.5-H   (IX.sub.5) in the respective molar proportions a.sub.1, a.sub.2, a.sub.3, a.sub.4 and a.sub.5 such that: the sum a.sub.1+a.sub.2+a.sub.3+a.sub.4+a.sub.5 is equal to 1 and that the sum a.sub.1+2a.sub.2+3a.sub.3+4a.sub.4+5a.sub.5 is equal to x.

14. The pharmaceutical composition (E1) suitable for topical use as defined in claim 1, wherein said emulsifying surfactant (S.sub.1) consists of a composition (C′2) comprising, per 100% of its mass: from 10% to 50% by mass of at least one alkylpolyglycoside composition (C′1) represented by formula (X):
R.sub.1—O-(G).sub.x-H  (X) in which x represents a decimal number between 1.05 and 2.5, G represents a xylosyl or α,β-D-xylopyranosyl radical, obtained from the removal of the hemiacetal hydroxyl group from α,β-D-xylopyranose, and R.sub.1 represents a 2-octyldodecyl radical, said composition consisting of a mixture of compounds represented by formulae (X.sub.1), (X.sub.2), (X.sub.3), (X.sub.4) and (X.sub.5):
R.sub.1—O-(G).sub.1-H   (X.sub.1)
R.sub.1—O-(G).sub.2-H   (X.sub.2)
R.sub.1—O-(G).sub.3-H   (X.sub.3)
R.sub.1—O-(G).sub.4-H   (X.sub.4)
R.sub.1—O-(G).sub.5-H   (X.sub.5) in the respective molar proportions a.sub.1, a.sub.2, a.sub.3, a.sub.4 and a.sub.5 such that: the sum a.sub.1+a.sub.2+a.sub.3+a.sub.4+a.sub.5 as is equal to 1 and that the sum a.sub.1+2a.sub.2+3a.sub.3+4a.sub.4+5a.sub.5 is equal to x; and from 50% to 90% by mass of at least one fatty alcohol of formula (XI):
R′″.sub.1—OH  (XI), in which R′″.sub.1 represents a 2-octyldodecyl radical.

15. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the emulsifying surfactant (S.sub.2) consists of at least one polyglycol polyhydroxystearate represented by formula (XIV): ##STR00030## in which y2 represents an integer greater than or equal to 2 and less than or equal to 50, R.sub.4 represents a hydrogen atom, a methyl radical or an ethyl radical, and Z.sub.2 represents a radical of formula (XV): ##STR00031## in which y′.sub.2 represents an integer greater than or equal to 0 and less than or equal to 10, and Z′.sub.2 represents a radical of formula (XV) as defined above, with Z′.sub.2 being identical to or different from Z.sub.2, or a hydrogen atom.

16. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, wherein the mass ratio between the emulsifying surfactant (S1) and the emulsifying surfactant (S2) is greater than or equal to ¼ and greater than or equal to 1.

17. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, for human or animal therapeutic use.

18. A method for reducing and/or eliminating local pains, post-traumatic inflammation of the joints, muscles, tendons or ligaments, localized forms of soft-tissue rheumatism, localized forms of degenerative rheumatic diseases, actinic keratosis caused by overexposure to sunlight, acute migraine, pain associated with bone metastases, fever due to malignant lymphogranulomatosis (Hodgkin's lymphoma), multi-drug resistant E. coli, Shy-Drager syndrome and diabetes mellitus, the method comprising applying an effective dose of the pharmaceutical composition of claim 1 to a patient in need thereof.

19. The pharmaceutical composition (E1) suitable for topical use as claimed in claim 1, further comprising at least one or more auxiliary compounds chosen from foaming and/or detergent surfactants, thickening and/or gelling surfactants, thickening and/or gelling agents, stabilizers, film-forming compounds, solvents and cosolvents, hydrotropic agents, plasticizers, opacifiers, nacreous agents, superfatting agents, sequestrants, chelating agents, antioxidants, fragrances, essential oils, preserving agents, conditioners, deodorants, mineral fillers or pigments.

20. A device which is in a form chosen from a jar, a pump-bottle, a wipe, a mask, a transdermal device, a patch, a poultice, a compress, a tube or a spray, said device comprising a pharmaceutical composition as defined in claim 1.

Description

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Preparation and Evaluation of Emulsions According to the Invention and Comparative Emulsions

1) Preparation of the Emulsions According to the Invention and of the Comparative Emulsions

[0149] Three emulsions according to the invention, denoted (F.sub.1) to (F.sub.3), and four comparative emulsions, denoted (F′.sub.1) to (F′.sub.3), the mass proportions of the constituents of which are collated in table 1 below, the mass contents of the polyelectrolytes being indicated as a percentage of polymeric solids, are prepared by performing the process below.

[0150] The constituents of the fatty phase are introduced successively into a beaker, mixed and brought to a temperature of 20° C. after an 80° C. heating step; the mixing is performed using a mechanical stirrer equipped with an impeller-type stirring spindle at a speed of 100 rpm. The constituents of the dispersed phase are mixed at room temperature in a beaker using a mechanical stirrer at a speed of 2000 rpm and the thickener is then added gradually. The stirring is maintained for a duration which makes it possible to obtain a phase which is in the form of a homogeneous gel. The fatty phase is added in one go to the gel at room temperature and at a moderate stirring speed (75 to 300 rpm) using a stirrer equipped with an anchor-type spindle. This stirring is then maintained for 10 minutes and no cooling step is necessary.

TABLE-US-00001 TABLE 1 (F.sub.1) (F.sub.2) (F.sub.3) (F′.sub.1) (F′.sub.2) (F′.sub.3) Continuous fatty phase Lanol ™ 2681.sup.(1) 15% 15% 15% 15% 15% 15% Sepineo ™ SE 68.sup.(2)  1%  0%  0%  0%  0% .sup.  0% Sepicide ™ HB.sup.(3)  1%  1%  1%  1%  1% .sup.  1% Simaline ™WO.sup.(4)  3%  3%  3%  3%  3% .sup.  3% Montane ™80.sup.(6)  0%  0%  0%  1%  1% .sup.  1% Montanov ™202.sup.(8)  0%  1%  0%  0%  0% .sup.  0% Fluidanov′20X.sup.(9)  0%  0%  1%  0%  0% .sup.  0% Dispersed phase Sepineo ™P600.sup.(5)  4%  4%  4%  4%  4% .sup.  4% PEG-400.sup.7  0%  0%  0%  0%  0% 50% Glycerol  0%  0%  0%  0% 60% .sup.  0% Water  0%  0%  0%  0% 15% 25% Diclofenac sodium  1%  1%  1%  1%  .sup.   1%.sup.(*.sup.) .sup.   1%.sup.(*.sup.) 1,2-Propanediol 75% 75% 75% 75%  0% .sup.  0% .sup.(1)Lanol ™ 2681, or cocoyl caprylate/caprate. .sup.(2)Sepineo ™ SE 68 is a mixture comprising, per 100% of its mass, from 78% to 85% by mass of a mixture of n-hexadecanol and n-octadecanol, and from 15% to 22% by mass of a mixture of n-hexadecyl glucoside with a mean degree of polymerization of 1.20 and n-octadecyl glucoside with a mean degree of polymerization of 1.20, used as emulsifying agent. .sup.(3)Sepicide ™ HB is a mixture of phenoxyethanol, methylparaben, ethylparaben, butylparaben and n-propylparaben, used as a preserving agent. .sup.(4)Simaline ™WO, or PEG 30 Dipolyhydroxystearate, is an emulsifying surfactant. .sup.(5)Sepineo ™ P600 is a self-invertible inverse latex comprising, per 100% of its mass, between 30% and 40% by mass of a crosslinked copolymer of acrylamide and of sodium acryloyldimethyltaurate, used as a thickener. .sup.(6)Montane ™ 80 is a composition comprising sorbitan monooleate, used as a water-in-oil type emulsifier. .sup.(7)PEG-400 is a polyethylene glycol with a molecular weight of about 400 g.mol.sup.−1. .sup.(8)Montanov ™ 202 is a mixture comprising, per 100% of its mass, from 80% to 90% by massof a mixture of arachidyl alcohol and behenyl alcohol, and from 10% to 20% by mass of arachidyl polyglucosides with a mean degree of polymerization of 1.20, used as an emulsifier. .sup.(9)Fluidanov ™ 20X is a mixture comprising, per 100% of its mass, from 70% to 90% by massof 2-octyl-1-dodecanol and from 10% to 30% by mass of 2-octyl-1-dodecanyl polyxyloside. .sup.(*.sup.)minimum mass proportion of water that could be added to the respective comparativeemulsions (F′.sub.2) and (F′.sub.3) without either obtaining gelation preventing stirring of said emulsion, or obtaining an emulsion having a heterogeneous appearance that persists despite the stirring phases of the preparation process, or a form for which the dispersedphase is the fatty phase.
2) Demonstration of the Properties of Emulsions (F.sub.1) to (F.sub.3) According to the Invention and of Comparative Emulsions (F′.sub.1) to (F′.sub.3) 2.1 Characterization of the Appearance and Viscosity of Emulsions (F.sub.1) to (F.sub.3) According to the Invention and of Comparative Emulsions (F′.sub.1) to (F′.sub.3).

[0151] The emulsions (F.sub.1) to (F.sub.3) and (F′.sub.1) to (F′.sub.3) obtained according to the process described previously are then stored in an insulated climatic chamber regulated at a temperature of 25° C. for 3 months. On conclusion of this period of three months, the appearance (APP) of each emulsion prepared is observed and the dynamic viscosity (μ) of each emulsion is measured (in mPa.Math.s) by means of a viscometer at 25° C. (Brookfield LVT, speed 6). An aliquot of these same emulsions (F.sub.1) to (F.sub.3) and (F′.sub.1) to (F′.sub.3) obtained according to the process described above are also stored in an insulated climatic chamber regulated at a temperature of 45° C. for three months. On conclusion of this period of three months, the appearance (APP) of each emulsion prepared is observed and the dynamic viscosity (μ) of each emulsion is measured (in mPa.Math.s) by means of a viscometer at 25° C. (Brookfield LVT, speed 6).

2.2 Characterization of the Direction of the Emulsions (F.sub.1) to (F.sub.3) According to the Invention and of the Comparative Emulsions (F′.sub.1) to (F′.sub.3).

[0152] The conductivity (σ) of the emulsions (F.sub.1) to (F.sub.3) according to the invention and of the emulsions (F′1) to (F′3) is measured at 25° C., after a period of storage of said emulsions of one day in an insulated climatic chamber regulated at a temperature of 25° C., by means of an LF 196™ brand conductivity meter from the company WTW equipped with a TetraCon™ 96 electrode. If, for a given emulsion, (σ)≤0.5 μS.cm.sup.−1, the emulsion is considered to be non-conductive and consequently the external phase is not the phase based on 1,2-propanediol but the oily phase. Indeed, the conductivity, measured at 25° C., of 1,2-propanediol is equal to 4400 μS.cm.sup.−1.

[0153] If, for a given emulsion, (σ)>0.5 μS.cm.sup.−1, the emulsion is considered to be conductive and consequently the external phase is not the oily phase but the phase based on 1,2-propanediol or glycerol or PEG-400.

[0154] This same measurement of the conductivity of the emulsions (F.sub.1) to (F.sub.3) according to the invention and of the comparative emulsions (F′.sub.1) to (F′.sub.3) is measured at 25° C. after three months at 25° C., and after three months at 45° C.

2.3 Results Obtained for the Emulsions (F.sub.1) to (F.sub.3) According to the Invention and for the Comparative Emulsions (F′.sub.1) to (F′.sub.3).

[0155] The evaluation methods described in sections 2.1 and 2.2 were applied to the emulsions (F.sub.1) to (F.sub.3) according to the invention and to the comparative emulsions (F′.sub.1) to (F′.sub.3). The results obtained are collated in table 2 below.

TABLE-US-00002 TABLE 2 (F.sub.1) (F.sub.2) (F.sub.3) (F′.sub.1) (F′.sub.2) (F′.sub.3) (APP) at Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous 1 day liquid liquid liquid liquid liquid liquid (visual) (σ) at 1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 >0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 day at m-1 1 -1 25° C. Dispersed Glycolic Glycolic Glycolic Fatty phase Glycolic Glycolic phase phase phase phase phase phase (APP) at Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous 7 days liquid liquid liquid liquid liquid liquid at 25° C. (σ) at 3 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 >0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 months at 25° C. (μ) at 3 40 000 44 800 mPa.s 51 000 not not not months mPas mPa.s measured measured measured at 25° C. (APP) at Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous Homogeneous 3 months liquid liquid liquid liquid liquid liquid at 45° C. (σ) at 3 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 >0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 ≤0.5 μS.cm.sup.−1 months at 45° C.

2.4 Analysis of the Results

[0156] The emulsions (F.sub.1) to (F.sub.3) according to the invention are thus characterized by: [0157] a stability of their form, of the type phase based on 1,2-propanediol dispersed in oil, after storage for 3 months at a temperature of 25° C.; the appearance observed after this storage period is still homogeneous; [0158] a stability of their form, of the type phase based on 1,2-propanediol dispersed in oil, after storage for 3 months at a temperature of 45° C.; the appearance observed after this storage period is still homogeneous;

[0159] The comparative emulsion (F′.sub.1) comprising sorbitan monooleate as water-in-oil lipophilic surfactant does not make it possible to obtain an emulsion in which the dispersed phase is the phase based on 1,2-propanediol.

[0160] The comparative emulsions (F′.sub.2) and (F′.sub.3), also comprising sorbitan monooleate as lipophilic surfactant, make it possible to obtain an emulsion in which the dispersed phase is the phase based on 1,2-propanediol, but a minimum an amount of water is necessary.